By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Goldman Sachs today upgraded PerkinElmer and Affymetrix but downgraded Thermo Fisher Scientific.

In a report outlining its outlook for 2012 in the broad medical technology space, analysts Isaac Ro and David Roman upgraded the investment firm's rating for PerkinElmer to Buy from Neutral, saying changes it has made in recent years has left it well positioned in the coming year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.